The present invention provides improved, methods to treat glioblastoma, including newly diagnosed glioblastoma (ndGBM) and recurrent glioblastoma (rGBM), in a human comprising administration to the patient of a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus 5' untranslated region between the poliovirus cloverleaf and the poliovirus open reading frame (a "chimeric poliovirus") by cervical perilymphatic subcutaneous injection, convection enhanced delivery (CED), direct intracavitary infusion via an Ommaya reservoir inserted into the surgical cavity, injection into the glioblastoma lesion cavity wall, or a combination thereof As provided herein, the chimeric poliovims is administered in a specifically-timed treatment regime comprising a treatment phases as a first-line treatment preceding the current standard of care glioblastoma therapy of maximum surgical resection, radiation, and temozolomide.
- 출원번호 : US2024/038857
- 출원인 : ISTARI ONCOLOGY, INC.;DUKE UNIVERSITY;
- 특허번호 :
- IPC : A61K-035/768(2015.01);A61K-039/13(2006.01);A61P-035/00(2006.01);A61K-031/495(2006.01);